Clinical trialNCT02363439CompletedPhase 1/PHASE2Interventional

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

SponsorIdera Pharmaceuticals, Inc.Enrollment5Waldenstrom's Macroglobulinemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mark Cornfeld, MD, MPH
Idera Pharmaceuticals, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2014
Primary completion: 31 Dec 2016
Completion: 31 Dec 2016
Last update posted: 9 Jan 2018
Registered enrollment: 5
Registry id: NCT02363439

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.